Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in Oncogene Retrieve available abstracts of 37 articles: HTML format

Single Articles

September 2025
1. LIU J, Ning J, Wang Y, He X, et al
   FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation.
   Oncogene. 2025 Sep 13. doi: 10.1038/s41388-025-03564.
   PubMed     Abstract available
   
   
   
2. HUANG L, Zhu M, Chen M, Ying F, et al
   LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.
   Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561.
   PubMed     Abstract available
   
   
   August 2025
3. LABUDA SE, Broaddus RR, Gladden AB
   ARID1A: gene, protein, and function in endometrial cancer.
   Oncogene. 2025 Aug 18. doi: 10.1038/s41388-025-03539.
   PubMed     Abstract available
   
   
   
4. LI Q, Zhang S, Wang M, Yi Q, et al
   Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
   Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
   PubMed     Abstract available
   
   
   July 2025
5. SHEN C, Cao R, Zhou Q, Zhou T, et al
   LINC00654 promotes ovarian cancer progression by facilitating nuclear export of HuR and stabilizing oncogenic mRNAs.
   Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03500.
   PubMed     Abstract available
   
   
   May 2025
6. SONG C, Lin Y, Cai C, Tao K, et al
   LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
   Oncogene. 2025 May 31. doi: 10.1038/s41388-025-03466.
   PubMed     Abstract available
   
   
   
7. NARAYANA RVL, Gupta R
   Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.
   Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448.
   PubMed     Abstract available
   
   
   
8. ZHANG C, Jiang H, Yuan L, Liao Y, et al
   Correction: CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability.
   Oncogene. 2025 May 15. doi: 10.1038/s41388-025-03440.
   PubMed    
   
   
   April 2025
9. ZHU Y, Abedini A, Rodriguez GM, McCloskey CW, et al
   Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.
   Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03387.
   PubMed     Abstract available
   
   
   
10. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    PubMed     Abstract available
    
    
    
11. WAGNER V, Morton M, Dorayappan KDP, Gonzalez A, et al
    Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03382.
    PubMed     Abstract available
    
    
    March 2025
12. ZHAO X, Lai H, Li G, Qin Y, et al
    Rictor orchestrates beta-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer.
    Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03351.
    PubMed     Abstract available
    
    
    
13. WANG J, Yang F, Chen Y, Xing Y, et al
    A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer.
    Oncogene. 2025 Mar 19. doi: 10.1038/s41388-025-03342.
    PubMed     Abstract available
    
    
    
14. ZHAI F, Li Y, Zheng J, Yan C, et al
    SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance in endometrial cancer by inducing O-dysglycosylation.
    Oncogene. 2025 Mar 17. doi: 10.1038/s41388-025-03347.
    PubMed     Abstract available
    
    
    
15. FANG D, Chen H, Zhu JY, Wang W, et al
    Editorial Expression of Concern: Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03333.
    PubMed    
    
    
    February 2025
16. XI Q, Kunita A, Ogawa M, Ka M, et al
    Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
    Oncogene. 2025 Feb 24. doi: 10.1038/s41388-025-03312.
    PubMed     Abstract available
    
    
    
17. STEWART J, Krastev DB, Brough R, Zatreanu D, et al
    PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-024-03265.
    PubMed     Abstract available
    
    
    January 2025
18. DONG P, Xiong Y, Yu J, Chen L, et al
    Editorial Expression of Concern: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
    Oncogene. 2025 Jan 29. doi: 10.1038/s41388-025-03285.
    PubMed    
    
    
    
19. WANG M, Yan Q, Song Y, Zhang Z, et al
    Correction: Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
    Oncogene. 2025 Jan 27. doi: 10.1038/s41388-025-03280.
    PubMed    
    
    
    
20. HAN X, Xia L, Wu Y, Chen X, et al
    m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways.
    Oncogene. 2025 Jan 15. doi: 10.1038/s41388-024-03260.
    PubMed     Abstract available
    
    
    December 2024
21. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    PubMed     Abstract available
    
    
    
22. CHIA ML, Bulat F, Gaunt A, Ros S, et al
    Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.
    Oncogene. 2024 Dec 6. doi: 10.1038/s41388-024-03231.
    PubMed     Abstract available
    
    
    
23. DUAN Q, Wang W, Xiong H, Xiao J, et al
    JAK2/ULK1 axis promotes cervical cancer progression by autophagy induction and SRPK1 phosphorylation.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03246.
    PubMed     Abstract available
    
    
    October 2024
24. SAKAUE T, Dorayappan KDP, Zingarelli R, Khadraoui W, et al
    Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
    Oncogene. 2024 Oct 16. doi: 10.1038/s41388-024-03182.
    PubMed     Abstract available
    
    
    
25. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    PubMed     Abstract available
    
    
    
26. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    PubMed     Abstract available
    
    
    
27. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    PubMed     Abstract available
    
    
    
28. SUN X, Ye G, Li J, Yuan L, et al
    The tumor suppressor Parkin exerts anticancer effects through regulating mitochondrial GAPDH activity.
    Oncogene. 2024;43:3215-3226.
    PubMed     Abstract available
    
    
    September 2024
29. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    PubMed     Abstract available
    
    
    
30. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    PubMed     Abstract available
    
    
    August 2024
31. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    PubMed     Abstract available
    
    
    June 2024
32. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    PubMed     Abstract available
    
    
    May 2024
33. PATTERSON MR, Meijers AS, Ryder EL, Wootton LM, et al
    E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.
    Oncogene. 2024 May 24. doi: 10.1038/s41388-024-03067.
    PubMed     Abstract available
    
    
    
34. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    PubMed     Abstract available
    
    
    April 2024
35. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    PubMed     Abstract available
    
    
    
36. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    PubMed     Abstract available
    
    
    
37. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.